NCT00866294View on ClinicalTrials.gov

Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Depressive Disorder
Interventions
DRUG

paroxetine IR 10mg tablet

1 or 2 tablets once a day

DRUG

paroxetine IR 20mg tablet

1 tablet once a day

DRUG

matched placebo to paroxetine IR 10mg or 20mg

1 or 2 tablets once a day

DRUG

Paroxetine CR 12.5mg tablet

1 or 2 tablets once a day

DRUG

Paroxetine CR 25mg tablet

1 or 2 tablets once a day

DRUG

matched placebo to paroxetine CR 12.5mg or 25mg

1 or 2 tablets once a day

Trial Locations (67)

453-0015

GSK Investigational Site, Aichi

468-0045

GSK Investigational Site, Aichi

479-0837

GSK Investigational Site, Aichi

272-0133

GSK Investigational Site, Chiba

802-0084

GSK Investigational Site, Fukuoka

802-8533

GSK Investigational Site, Fukuoka

810-0001

GSK Investigational Site, Fukuoka

810-0022

GSK Investigational Site, Fukuoka

811-0121

GSK Investigational Site, Fukuoka

815-0041

GSK Investigational Site, Fukuoka

819-0167

GSK Investigational Site, Fukuoka

379-0115

GSK Investigational Site, Gunma

060-0003

GSK Investigational Site, Hokkaido

060-0042

GSK Investigational Site, Hokkaido

063-0804

GSK Investigational Site, Hokkaido

651-0097

GSK Investigational Site, Hyōgo

657-0846

GSK Investigational Site, Hyōgo

660-0882

GSK Investigational Site, Hyōgo

311-3193

GSK Investigational Site, Ibaraki

220-0004

GSK Investigational Site, Kanagawa

221-0835

GSK Investigational Site, Kanagawa

223-0052

GSK Investigational Site, Kanagawa

231-0023

GSK Investigational Site, Kanagawa

238-0042

GSK Investigational Site, Kanagawa

244-0816

GSK Investigational Site, Kanagawa

251-0055

GSK Investigational Site, Kanagawa

861-8002

GSK Investigational Site, Kumamoto

616-8421

GSK Investigational Site, Kyoto

390-0303

GSK Investigational Site, Nagano

399-8695

GSK Investigational Site, Nagano

530-0041

GSK Investigational Site, Osaka

569-7711

GSK Investigational Site, Osaka

582-0025

GSK Investigational Site, Osaka

589-0011

GSK Investigational Site, Osaka

840-0816

GSK Investigational Site, Saga

843-0023

GSK Investigational Site, Saga

331-0081

GSK Investigational Site, Saitama

332-0012

GSK Investigational Site, Saitama

350-0046

GSK Investigational Site, Saitama

366-0824

GSK Investigational Site, Saitama

321-0953

GSK Investigational Site, Tochigi

100-0006

GSK Investigational Site, Tokyo

107-0052

GSK Investigational Site, Tokyo

135-0061

GSK Investigational Site, Tokyo

141-0021

GSK Investigational Site, Tokyo

142-0051

GSK Investigational Site, Tokyo

151-0053

GSK Investigational Site, Tokyo

152-0012

GSK Investigational Site, Tokyo

154-0004

GSK Investigational Site, Tokyo

165-0033

GSK Investigational Site, Tokyo

166-0003

GSK Investigational Site, Tokyo

167-0042

GSK Investigational Site, Tokyo

167-0051

GSK Investigational Site, Tokyo

170-0002

GSK Investigational Site, Tokyo

173-0037

GSK Investigational Site, Tokyo

180-0005

GSK Investigational Site, Tokyo

192-0082

GSK Investigational Site, Tokyo

682-0023

GSK Investigational Site, Tottori

501-757

GSK Investigational Site, Gwangju

110-744

GSK Investigational Site, Seoul

110-746

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

150-713

GSK Investigational Site, Seoul

156-707

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00866294 - Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study) | Biotech Hunter | Biotech Hunter